Target Name: KIAA1614
NCBI ID: G57710
Other Name(s): RP11-46A10.3 | K1614_HUMAN | Uncharacterized protein KIAA1614

KIAA1614: A Potential Drug Target for Neurological Disorders

KIAA1614 (RP11-46A10.3) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and pancreas. It is a member of the KIAA family of proteins, which are involved in the intracellular signaling pathway known as the K+ channel regulation.

KIAA1614 is known for its role in regulating the activity of the neurotransmitter acetylcholine, which is involved in the development and maintenance of memories and learning. In addition, KIAA1614 has also been shown to play a role in the regulation of ion channels, including the sodium (Na+) and potassium (K+) channels.

The research on KIAA1614 has led to the hypothesis that it may be a drug target or biomarker for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. This is because the disruption of KIAA1614 has been observed to be associated with the development of these disorders, and its inhibition has been shown to improve the symptoms in animal models of these conditions.

In addition to its potential therapeutic applications, KIAA1614 has also been shown to be a potential biomarker for these disorders. The levels of KIAA1614 have been found to be decreased in the brains of individuals with Alzheimer's disease and other neurological disorders. Furthermore, studies have shown that KIAA1614 is downregulated in the blood vessels of individuals with depression, and its levels are associated with the development of these conditions.

The precise mechanism by which KIAA1614 is involved in the regulation of neurotransmitters and ion channels is not yet fully understood. However, it is known that KIAA1614 plays a role in the regulation of the activity of the neurotransmitter acetylcholine, which is involved in the development and maintenance of memories and learning.

In addition, KIAA1614 has also been shown to play a role in the regulation of ion channels, including the sodium (Na+) and potassium (K+) channels. The disruption of KIAA1614 has been observed to be associated with the development of certain ion channels, including the sodium channels that are involved in the regulation of muscle and nerve activity.

Overall, the research on KIAA1614 has led to the hypothesis that it may be a drug target or biomarker for various neurological and psychiatric disorders. Its potential therapeutic applications and biomarker potential make it an important area of 鈥嬧?媟esearch for the development of new treatments for these conditions .

Protein Name: KIAA1614

More Common Targets

KIAA1656 | KIAA1671 | KIAA1671-AS1 | KIAA1755 | KIAA1958 | KIAA2012 | KIAA2013 | KIAA2026 | KICS2 | KIDINS220 | KIF11 | KIF12 | KIF13A | KIF13B | KIF14 | KIF15 | KIF16B | KIF17 | KIF18A | KIF18B | KIF19 | KIF1A | KIF1B | KIF1C | KIF20A | KIF20B | KIF21A | KIF21B | KIF22 | KIF23 | KIF23-AS1 | KIF24 | KIF25 | KIF25-AS1 | KIF26A | KIF26B | KIF27 | KIF28P | KIF2A | KIF2B | KIF2C | KIF3A | KIF3B | KIF3C | KIF4A | KIF4B | KIF5A | KIF5B | KIF5C | KIF6 | KIF7 | KIF9 | KIF9-AS1 | KIFAP3 | KIFBP | KIFC1 | KIFC2 | KIFC3 | Killer Cell Immunoglobulin-Like Receptor (KIR) | Killer cell immunoglobulin-like receptor 2DS1, transcript variant X1 | KIN | Kinesin-like protein KIF16B (isoform 1) | KIR2DL1 | KIR2DL2 | KIR2DL3 | KIR2DL4 | KIR2DL5A | KIR2DL5B | KIR2DP1 | KIR2DS1 | KIR2DS2 | KIR2DS3 | KIR2DS4 | KIR2DS5 | KIR3DL1 | KIR3DL2 | KIR3DL3 | KIR3DP1 | KIR3DS1 | KIR3DX1 | KIRREL1 | KIRREL1-IT1 | KIRREL2 | KIRREL3 | KIRREL3-AS2 | KIRREL3-AS3 | KISS1 | KISS1R | KIT | KITLG | KIZ | KIZ-AS1 | KL | KLB | KLC1 | KLC2 | KLC3 | KLC4 | KLF1 | KLF10